Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Breast Cancer: A Plain Language Summary of the DESTINY-Breast03 Study
Future Oncology · 2024
DOI: 10.2217/fon-2023-0422 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, 2024. Verfasst von Javier Cortés. Beteiligte Einrichtung: Oncology Department, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms, Camptothecin, Immunoconjugates, Lung Diseases, Interstitial. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
WHAT IS THIS SUMMARY ABOUT?: This is a summary of a publication about the DESTINY-Breast03 study, which was published in the New England Journal of Medicine in March 2022. The study included 524 adults with advanced breast cancer that is HER2-positive, which means it has high levels of a protein called HER2. All of the participants in this study had their cancer worsen after previously receiving treatment. The treatment that was previously given to participants was a combination of a drug called trastuzumab with a type of chemotherapy called a taxane. The researchers wanted to know whether a drug called trastuzumab deruxtecan (T-DXd) could improve participants' cancer more than the standard treatment. The standard treatment is a drug called trastuzumab emtansine (T-DM1). The researchers looked at the results of this study before it was finished. This is a summary of those results. WHAT WERE THE RESULTS?: Researchers in this study found that the risk of dying or the participants' cancer getting worse was reduced by 72% in the T-DXd group compared with the T-DM1 group. This is also called progression-free survival. 79.7% of participants in the T-DXd group had their tumors shrink significantly or disappear, compared to 34.2% of those in the T-DM1 group. During the study, 10.9% of participants who received T-DXd had serious drug-related medical problems, compared to 6.1% who received T-DM1. Of the participants who received T-DXd, 10.5% experienced drug-related interstitial lung disease (ILD) or pneumonitis, compared to 1.9% of those who received T-DM1. ILD and pneumonitis are potentially serious lung problems. When the researchers first looked at the results, they could not yet be certain that T-DXd helped participants survive longer overall than T-DM1. But, when they looked at the results later in the study, they found that T-DXd did help participants to survive longer overall than T-DM1. These newer results were published separately and are not part of this summary. A link to more information about the newer results can be found at the end of this summary. WHAT DO THE RESULTS MEAN?: T-DXd gave participants a meaningful benefit overall compared to T-DM1. T-DXd could be a treatment option for people with advanced HER2-positive breast cancer that has been previously treated. Clinical Trial Registration: NCT03529110 (DESTINY-Breast03) (ClinicalTrials.gov).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Department, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain.
Zitieren
APA
Cortés, J. (2024). Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Breast Cancer: A Plain Language Summary of the DESTINY-Breast03 Study. Future Oncology. https://doi.org/10.2217/fon-2023-0422
Vancouver
Cortés J. Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Breast Cancer: A Plain Language Summary of the DESTINY-Breast03 Study. Future Oncology. 2024. doi:10.2217/fon-2023-0422
BibTeX
@article{Corts2024,
author = {Cortés, Javier},
title = {Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Breast Cancer: A Plain Language Summary of the DESTINY-Breast03 Study},
journal = {Future Oncology},
year = {2024},
doi = {10.2217/fon-2023-0422}
}
EUVIMED